Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082955 | 0.92 | GAA (0.36) | GAAATMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6083689 | 0.86 | L3MBTL1 (0.44) | GAAKDM4EALDH1A1 | |
| SCHEMBL6081893 | 0.86 | CHRM4 (0.35) | KDM4E | |
| SCHEMBL6083397 | 0.84 | GAA (0.40) | GAAATMKDM4EALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL6082140 | 0.83 | L3MBTL1 (0.39) | KDM4E | |
| SCHEMBL6082072 | 0.82 | POLB (0.42) | — | |
| SCHEMBL6083005 | 0.81 | CD38 (0.41) | ALDH1A1 | |
| SCHEMBL4239462 | 0.81 | GAA (0.44) | GAAATMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6082378 | 0.76 | GAA (0.36) | GAAATMKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6082339 | 0.76 | CDK8 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | claimed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | claimed |
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | GPBAR1, ADRB3, ADRA1A | GAA 1030/4885ATM 2447/4885KDM4E 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.